Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform MALVERN, Pa.,…
O2 and Mavenir successfully trial technology to improve call clarity for people with hearing loss